Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of “Reduce” by Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been given a consensus rating of “Reduce” by the nine analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $14.00.

A number of brokerages have commented on VTYX. Clear Str downgraded shares of Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Wells Fargo & Company reiterated an “equal weight” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Canaccord Genuity Group cut shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $16.00 to $14.00 in a research report on Thursday, January 8th. Lifesci Capital reaffirmed a “market perform” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday, January 8th. Finally, Piper Sandler cut Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective for the company. in a research report on Thursday, January 8th.

Ventyx Biosciences Stock Down 0.1%

Ventyx Biosciences stock opened at $13.88 on Wednesday. The firm has a market cap of $990.48 million, a P/E ratio of -9.25 and a beta of 1.23. The business has a fifty day moving average of $9.97 and a two-hundred day moving average of $5.90. Ventyx Biosciences has a twelve month low of $0.78 and a twelve month high of $25.00.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. Equities analysts expect that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Insider Transactions at Ventyx Biosciences

In related news, insider John Nuss sold 12,675 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the transaction, the insider directly owned 489,481 shares of the company’s stock, valued at $3,778,793.32. This trade represents a 2.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This trade represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 18.18% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ventyx Biosciences

A number of large investors have recently bought and sold shares of VTYX. JPMorgan Chase & Co. raised its position in Ventyx Biosciences by 63.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 748,088 shares of the company’s stock worth $2,327,000 after buying an additional 290,169 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Ventyx Biosciences in the third quarter worth $61,000. Woodline Partners LP purchased a new position in shares of Ventyx Biosciences during the third quarter worth $143,000. XTX Topco Ltd lifted its position in Ventyx Biosciences by 25.2% during the third quarter. XTX Topco Ltd now owns 202,382 shares of the company’s stock valued at $629,000 after purchasing an additional 40,771 shares during the period. Finally, Vestal Point Capital LP boosted its holdings in Ventyx Biosciences by 2.5% in the third quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock valued at $6,376,000 after purchasing an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.